BioSpace20h
4DMT’S Gene Therapy for AMD Clears Phase II, Heads to Late-Stage Studies
D Molecular Therapeutics reported its experimental gene therapy demonstrated a nearly 90% reduction in the need for ...
FierceBiotech17h
In 2 papers, researchers describe potential new neurodegenerative disease treatment approach
The team engineered genes to code for the RING constructs and delivered them to mice using an adenovirus vector, commonly ...
Genprex Announces Formation of Mesothelioma Clinical Advisory Board
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...
The Lancet9h
Quantifying the effect of vector targeted interventions to control dengue
In The Lancet Infectious Diseases, Fernando Abad-Franch and colleagues1 present the results of a study that used distributions in case data to assess the effect of mosquito-disseminated pyriproxyfen ...
The EMBO Journal22h
A shorter splicing isoform antagonizes ZBP1 to modulate cell death and inflammatory responses
Mice express full-length protein ZBP1-L as well as an alternatively-spliced shorter isoform (ZBP1-S) containing only its two ...